Literature DB >> 8630591

Functional and binding characteristics of long-acting beta 2-agonists in lung and heart.

F J Roux1, B Grandordy, J S Douglas.   

Abstract

Salmeterol and formoterol, two new long-acting beta 2-agonists were equipotent (values of negative log molar concentration eliciting half-maximal effect [pD2] 9.2 +/- 0.03 and 8.9 +/- 0.03, respectively) in relaxing maximally contracted guinea pig tracheal spirals (histamine, 100 microM). Both agonists were 10 times more potent than L-isoproterenol and fenoterol and 100 times more potent than albuterol. L-Isoproterenol and fenoterol induced > 90% relaxation (percentage of maximal aminophylline relaxation). Formoterol and albuterol were equally efficacious. Formoterol was more efficacious (86 +/- 5%) than salmeterol (62 +/- 3%) or soterenol (59 +/- 3%). In minimally contracted tissues (10 microM histamine), agonist potencies increased 10-fold and relaxation was complete. In [125I]iodocyanopindolol-labeled bronchial membranes, formoterol and salmeterol induced high-affinity states of the beta 2-receptor (pKh 9.6 +/- 0.4 and 10.4 +/- 0.7, respectively), the former inducing a higher percentage (57 +/- 6 versus 28 +/- 4, p < 0.05). Only low-affinity binding (pKI) was observed when guanine nucleotide was present. pD2 values were similar to pKh values and relative efficacies significantly correlated with percentage of pKI sites. Formoterol and salmeterol were highly selective for the beta 2 versus beta 1-subtype (pKI values were 8.2 +/- 0.09 and 6.25 +/- 0.06 and 8.3 +/- 0.04 and 5.7 +/- 0.04, respectively). Albuterol (5.83 +/- 0.06 and 4.71 +/- 0.16) and fenoterol (6.33 +/- 0.07 and 5.67 +/- 0.05) were less selective. These results can explain the potencies and efficacies of salmeterol and formoterol in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630591     DOI: 10.1164/ajrccm.153.5.8630591

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  12 in total

1.  Anti-inflammatory effects of β2 adrenergic receptor agonists in experimental acute lung injury.

Authors:  Markus Bosmann; Jamison J Grailer; Ketong Zhu; Michael A Matthay; J Vidya Sarma; Firas S Zetoune; Peter A Ward
Journal:  FASEB J       Date:  2012-02-07       Impact factor: 5.191

2.  Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.

Authors:  Peter Molenaar; Lu Chen; William A Parsonage
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

3.  Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.

Authors:  James G Ryall; Martin N Sillence; Gordon S Lynch
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 4.  The role of inhaled long-acting beta-2 agonists in the management of asthma.

Authors:  H William Kelly; Michelle S Harkins; Homer Boushey
Journal:  J Natl Med Assoc       Date:  2006-01       Impact factor: 1.798

5.  Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.

Authors:  J A Bennett; A E Tattersfield
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

Review 6.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

7.  Identification and Characterization of Novel Bronchodilator Agonists Acting at Human Airway Smooth Muscle Cell TAS2R5.

Authors:  Donghwa Kim; Steven S An; Hong Lam; James W Leahy; Stephen B Liggett
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

8.  Speed of onset of bronchodilator response to salbutamol inhaled via different devices in asthmatics: a bioassay based on functional antagonism.

Authors:  Federico Lavorini; Pietro Geri; Laura Mariani; Cecilia Marmai; Nazzarena Maria Maluccio; Massimo Pistolesi; Giovanni A Fontana
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

9.  Chronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha).

Authors:  P A Finney; L E Donnelly; M G Belvisi; T T Chuang; M Birrell; A Harris; J C Mak; C Scorer; P J Barnes; I M Adcock; M A Giembycz
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

10.  Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.

Authors:  A R Guhan; S Cooper; J Oborne; S Lewis; J Bennett; A E Tattersfield
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.